Retatrutide vs Tirzepatide vs Semaglutide: Which Weight Loss Peptide Is Best?

A comprehensive comparison of the three most talked-about weight loss peptides — with clinical data, mechanisms, and practical considerations.

The Weight Loss Peptide Revolution

The GLP-1 receptor agonist class has transformed weight management. What started with Semaglutide (Ozempic/Wegovy) has evolved into a multi-receptor approach that is rewriting the rules of what's pharmacologically possible for body weight reduction.

Let's compare the three leading compounds.

Semaglutide — The Pioneer

Mechanism: Single GLP-1 receptor agonist

Clinical Results: ~15% body weight reduction in the STEP trials

Key Findings: Well-established safety profile with years of clinical data. FDA-approved for both diabetes (Ozempic) and weight management (Wegovy).

Tirzepatide — The Dual Agonist

Mechanism: Dual GLP-1 + GIP receptor agonist

Clinical Results: Up to 22.5% body weight reduction in the SURMOUNT-1 trial

Key Findings: The addition of GIP receptor activation amplifies the metabolic effect beyond what GLP-1 alone can achieve. Marketed as Mounjaro (diabetes) and Zepbound (weight management).

Retatrutide — The Triple Agonist

Mechanism: Triple GLP-1 + GIP + Glucagon receptor agonist

Clinical Results: Up to 24.2% body weight reduction in Phase 2 trials — the highest of any pharmacological intervention to date

Key Findings: The addition of glucagon receptor activation to the dual agonist framework accelerates fat oxidation while the GLP-1/GIP components handle appetite suppression and metabolic regulation. These results exceed most bariatric surgical outcomes.

Head-to-Head Comparison

Availability

Retatrutide is available at Peptides & You in 5mg (₱3,500), 10mg (₱4,500), and 15mg (₱6,500) vials. Lab tested, COA included.

For research purposes. Consult a healthcare professional before use.